Immunoglobulin Replacement Therapy in Antibody Production Defects
DOI:
https://doi.org/10.20344/amp.24119Keywords:
Immunoglobulins, Intravenous/therapeutic use, Precision Medicine, Primary Immunodeficiency DiseasesAbstract
Immunoglobulin replacement therapy is an essential approach for treating patients with inborn errors of immunity that impair humoral response. The main goal of immunoglobulin replacement treatment is to provide antibodies passively, preventing severe or recurrent infections, as well as medium/long-term complications. Currently, there are different administration routes: intravenous, conventional subcutaneous, and facilitated subcutaneous with recombinant hyaluronidase. Therefore, the choice of the administration route should be individualized, with the active participation of the patient and guidance from healthcare professionals regarding the advantages and limitations of each option. This guideline aims to clarify the available immunoglobulin treatment modalities, provide practical guidance for their selection, and thereby promote better treatment adherence and effectiveness, leading to improved clinical stability for patients.
Downloads
References
Buckley CR. Agammaglobulinemia, by Col. Ogden C. Bruton, MC, USA, Pediatrics, 1952;9:722-728. Pediatrics. 1998;102:213-5. DOI: https://doi.org/10.1542/peds.102.S1.213
Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125:S182-94. DOI: https://doi.org/10.1016/j.jaci.2009.07.053
García JM, Gamboa P, de la Calle A, Hernández MD, Caballero MT, García BE, et al. Diagnosis and management of immunodeficiencies in adults by allergologists. J Investig Allergol Clin Immunol. 2010;20:185-94.
Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy. J Allergy Clin Immunol. 2006;117:S525-53. Erratum in: J Allergy Clin Immunol. 2006;117:1483. DOI: https://doi.org/10.1016/j.jaci.2006.01.015
Wasserman RL. Personalized therapy: immunoglobulin replacement for antibody deficiency. Immunol Allergy Clin North Am. 2019;39:95-111. DOI: https://doi.org/10.1016/j.iac.2018.08.001
Herman KE, Tuttle KL. Overview of secondary immunodeficiency. Allergy Asthma Proc. 2024;45:347-54. DOI: https://doi.org/10.2500/aap.2024.45.240063
Seidel MG. Rethinking PIDs: why the distinction between primary and secondary immune disorders is more frequently relevant than that between inborn and acquired errors of immunity. J Allergy Clin Immunol. 2024;153:1543-45. DOI: https://doi.org/10.1016/j.jaci.2024.01.018
Patel SY, Carbone J, Jolles S. The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Front Immunol. 2019;10:33. DOI: https://doi.org/10.3389/fimmu.2019.00033
Demirdag YY, Gupta S. Update on infections in primary antibody deficiencies. Front Immunol. 2021;12:634181. DOI: https://doi.org/10.3389/fimmu.2021.634181
Lee JL, Mohamed Shah N, Makmor-Bakry M, Islahudin FH, Alias H, Noh LM et al. A systematic review and meta-regression analysis on the impact of increasing IgG trough level on infection rates in primary immunodeficiency patients on intravenous IgG therapy. J Clin Immunol. 2020;40:682-98. DOI: https://doi.org/10.1007/s10875-020-00788-5
Ponsford MJ, Price C, Farewell D, Greene G, Moore C, Perry M, et al. Increased respiratory viral detection and symptom burden among patients with primary antibody deficiency: results from the BIPAD study. J Allergy Clin Immunol Pract. 2021;9:735-44.e6. DOI: https://doi.org/10.1016/j.jaip.2020.08.016
Sriaroon P, Ballow M. Immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am. 2015;35:713-30. DOI: https://doi.org/10.1016/j.iac.2015.07.006
Steinbuch M, Audran R. The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch Biochem Biophys. 1969;134:279-84. DOI: https://doi.org/10.1016/0003-9861(69)90285-9
Dhainaut F, Guillaumat PO, Dib H, Perret G, Sauger A, de Coupade C, et al. In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations. Vox Sang. 2013;104:115-26. DOI: https://doi.org/10.1111/j.1423-0410.2012.01648.x
Späth PJ, Granata G, La Marra F, Kuijpers TW, Quinti I. On the dark side of therapies with immunoglobulin concentrates: the adverse events. Front Immunol. 2015;6:11. DOI: https://doi.org/10.3389/fimmu.2015.00011
Bonilla FA. Intravenous and subcutaneous immunoglobulin G replacement therapy. Allergy Asthma Proc. 2016;37:426-31. DOI: https://doi.org/10.2500/aap.2016.37.3987
Borte M, Bernatowska E, Ochs HD, Roifman CM; Vivaglobin Study Group. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies. Clin Exp Immunol. 2011;164:357-64. DOI: https://doi.org/10.1111/j.1365-2249.2011.04376.x
Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20:94-100. DOI: https://doi.org/10.1023/A:1006678312925
Shapiro RS. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Ann Allergy Asthma Immunol. 2013;111:51-5. DOI: https://doi.org/10.1016/j.anai.2013.04.015
Krivan G, Jolles S, Granados EL, Paolantonacci P, Ouaja R, Cissé AO, et al. New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients. Am J Clin Exp Immunol. 2017;6:76-83.
Sil A, Basu S, Joshi V, Pilania RK, Siniah S, Suri D, et al. Immunoglobulin replacement therapies in inborn errors of immunity: a review. Front Pediatr. 2024;12:1368755. DOI: https://doi.org/10.3389/fped.2024.1368755
Shapiro RS, Wasserman RL, Bonagura V, Gupta S. Emerging paradigm of primary immunodeficiency disease: individualizing immunoglobulin dose and delivery to enhance outcomes. J Clin Immunol. 2017;37:190-6. DOI: https://doi.org/10.1007/s10875-014-9990-x
Jolles S, Orange JS, Gardulf A, Stein MR, Shapiro R, Borte M, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol. 2015;179:146-60. DOI: https://doi.org/10.1111/cei.12485
Yalcin Gungoren E, Yorgun Altunbas M, Dikici U, Meric Z, Eser Simsek I, Kiykim A, et al. Insights into patient experiences with facilitated subcutaneous immunoglobulin therapy in primary immune deficiency: a prospective observational cohort. J Clin Immunol. 2024;44:169. DOI: https://doi.org/10.1007/s10875-024-01771-0
Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139:S1-S46. DOI: https://doi.org/10.1016/j.jaci.2016.09.023
Perez E. Future of therapy for inborn errors of immunity. Clin Rev Allergy Immunol. 2022;63:75-89. DOI: https://doi.org/10.1007/s12016-021-08916-8
Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27:171-8. DOI: https://doi.org/10.1016/j.tmrv.2013.05.004
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
